{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:06:24Z","timestamp":1791522384122,"version":"4.3.4"},"reference-count":63,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Over the past 10 years, it has become increasingly evident that nonalcoholic fatty liver disease (NAFLD) is a multisystem disease that affects multiple extra-hepatic organ systems and interacts with the regulation of several metabolic and immunological pathways. In this review we discuss the rapidly expanding body of clinical and epidemiological evidence supporting a strong association between NAFLD and chronic plaque psoriasis. We also briefly discuss the possible biological mechanisms underlying this association, and discuss treatment options for psoriasis that may influence NAFLD development and progression. Recent observational studies have shown that the prevalence of NAFLD (as diagnosed either by imaging or by histology) is remarkably higher in psoriatic patients (occurring in up to 50% of these patients) than in matched control subjects. Notably, psoriasis is associated with NAFLD even after adjusting for metabolic syndrome traits and other potential confounding factors. Some studies have also suggested that psoriatic patients are more likely to have the more advanced forms of NAFLD than non-psoriatic controls, and that psoriatic patients with NAFLD have more severe psoriasis than those without NAFLD. In conclusion, the published evidence argues for more careful evaluation and surveillance of NAFLD among patients with psoriasis.<\/jats:p>","DOI":"10.3390\/ijms17020217","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T10:06:16Z","timestamp":1454666776000},"page":"217","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?"],"prefix":"10.3390","volume":"17","author":[{"given":"Alessandro","family":"Mantovani","sequence":"first","affiliation":[{"name":"Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Stefani, 1, Verona 37126, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Stefani, 1, Verona 37126, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-0698","authenticated-orcid":false,"given":"Amedeo","family":"Lonardo","sequence":"additional","affiliation":[{"name":"Outpatient Liver Clinic and Division of Internal Medicine\u2014Department of Biomedical, Metabolic and Neural Sciences, NOCSAE, University of Modena and Reggio Emilia and Azienda USL Modena, Baggiovara, Modena 41126, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Stefani, 1, Verona 37126, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09546630701364768","article-title":"Psoriasis comorbidities","volume":"19","author":"Gottlieb","year":"2008","journal-title":"J. Dermatol. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Non-alcoholic fatty liver disease (NAFLD) Study Group, dedicated to the memory of Prof. Paola Loria, Lonardo, A., Bellentani, S., Argo, C.K., Ballestri, S., Byrne, C.D., Caldwell, S.H., Cortez-Pinto, H., Grieco, A., and Machado, M.V. (2015). Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig. Liver Dis., 47, 997\u20131006.","DOI":"10.1016\/j.dld.2015.08.004"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","article-title":"Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, T., Zhang, C., Tang, F., Zhong, N., Li, H., Song, X., Lin, H., Liu, Y., and Xue, F. (2015). Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open, 5.","DOI":"10.1136\/bmjopen-2015-008204"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., Roverato, A., Guaraldi, G., and Lonardo, A. (2015). Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol.","DOI":"10.1111\/jgh.13264"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3748\/wjg.v20.i7.1724","article-title":"Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease","volume":"20","author":"Ballestri","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ogdie, A., and Gelfand, J.M. (2015). Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidence. Curr. Rheumatol. Rep., 17.","DOI":"10.1007\/s11926-015-0540-1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2006","journal-title":"Arch. Dermatol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study","volume":"157","author":"Gisondi","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.molimm.2014.12.014","article-title":"Genetic and epigenetic basis of psoriasis pathogenesis","volume":"64","author":"Chandra","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Durham, L.E., Kirkham, B.W., and Taams, L.S. (2015). Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep., 17.","DOI":"10.1007\/s11926-015-0529-9"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1590-8658(01)80144-4","article-title":"Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI.ST.E.N.A. Study","volume":"33","author":"Lonardo","year":"2001","journal-title":"Dig. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00535-004-1451-5","article-title":"Nonalcoholic steatohepatitis associated with psoriasis vulgaris","volume":"39","author":"Matsumoto","year":"2004","journal-title":"J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","article-title":"Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Miele","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-0960.2012.00905.x","article-title":"The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: A study from South India","volume":"53","author":"Madanagobalane","year":"2012","journal-title":"Australas. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study","volume":"70","author":"Koehler","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Van der Voort, E.A., Koehler, E.M., Nijsten, T., Stricker, B.H., Hofman, A., Janssen, H.L., Schouten, J.N., and Wakkee, M. (2015). Increased prevalence of advanced liver fibrosis in patients with psoriasis: A cross-sectional analysis from the Rotterdam study. Acta Derm. Venereol.","DOI":"10.2340\/00015555-2161"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/jdv.13456","article-title":"Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis","volume":"30","author":"Gisondi","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/ced.12672","article-title":"Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease","volume":"40","author":"Abedini","year":"2015","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/apt.13042","article-title":"The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic","volume":"41","author":"Roberts","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jdv.12847","article-title":"Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis","volume":"29","author":"Candia","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes","volume":"59","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","article-title":"Inflammation and insulin resistance","volume":"116","author":"Shoelson","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-3083.2006.01499.x","article-title":"Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with types of psoriasis","volume":"20","author":"Ucak","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/ATVBAHA.114.303034","article-title":"Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: Implications for cardiovascular disease","volume":"34","author":"Byrne","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrgastro.2009.33","article-title":"Endocrine and liver interaction: The role of endocrine pathways in NASH","volume":"6","author":"Loria","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMra1011035","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shulmann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2012.258","article-title":"The role of hepatokines in metabolism","volume":"9","author":"Stefan","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/13880209.2014.960944","article-title":"A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation","volume":"53","author":"Kulkarni","year":"2015","journal-title":"Pharm. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2014Update 2015\u2014Short version\u2014EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Gisondi, P., Galvan, A., Idolazzi, L., and Girolomoni, G. (2015). Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front. Med., 2.","DOI":"10.3389\/fmed.2015.00001"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National psoriasis foundation consensus conference","volume":"60","author":"Kalb","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/toxsci\/kfu156","article-title":"Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis","volume":"142","author":"Hardwick","year":"2014","journal-title":"Toxicol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/j.1468-3083.2012.04450.x","article-title":"Psocare Study Group. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry","volume":"27","author":"Gisondi","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_45","first-page":"772","article-title":"Acitretin in dermatology: A review","volume":"10","author":"Dunn","year":"2011","journal-title":"J. Drugs Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00403-007-0784-3","article-title":"Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus","volume":"299","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1210\/jc.2010-1170","article-title":"TNF-\u03b1 antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome","volume":"96","author":"Stanley","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.2011.878","article-title":"Association between disease-modifying anti-rheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis","volume":"305","author":"Solomon","year":"2011","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1684\/ejd.2011.1548","article-title":"Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: A retrospective cohort study","volume":"21","author":"Lestre","year":"2011","journal-title":"Eur. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.12235","article-title":"Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab","volume":"26","author":"Tobon","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14656566.2016.1109636","article-title":"Novel systemic therapies for the treatment of psoriasis","volume":"17","author":"Tan","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00535-012-0678-9","article-title":"The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis","volume":"48","author":"Campanati","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/MEG.0000000000000421","article-title":"Nonalcoholic fatty liver disease: A potential consequence of tumor necrosis factor-inhibitor therapy","volume":"27","author":"Feagins","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000335566","article-title":"Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: A randomized, investigator-blinded study","volume":"224","author":"Gisondi","year":"2012","journal-title":"Dermatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of weight loss on the severity of psoriasis: A randomized clinical study","volume":"149","author":"Jensen","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/14712598.2014.900541","article-title":"The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial","volume":"14","author":"Nour","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/ebmed-2011-100388","article-title":"Thiazolidinediones for plaque psoriasis: A systematic review and meta-analysis","volume":"17","author":"Malhotra","year":"2012","journal-title":"Evid. Based Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nrgastro.2013.175","article-title":"Noninvasive evaluation of NAFLD","volume":"10","author":"Castera","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1586\/17474124.2015.1007955","article-title":"Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications","volume":"9","author":"Ballestri","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/17474124.2015.965143","article-title":"Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease","volume":"9","author":"Lonardo","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/2\/217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:18:53Z","timestamp":1760210333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/2\/217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2]]}},"alternative-id":["ijms17020217"],"URL":"https:\/\/doi.org\/10.3390\/ijms17020217","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]}}}